<DOC>
	<DOC>NCT01569295</DOC>
	<brief_summary>This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib or placebo. All subjects will be administered bendamustine and rituximab.</brief_summary>
	<brief_title>A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previously treated recurrent CLL Measurable lymphadenopathy Requires therapy for CLL Has experienced CLL progression &lt;36 months since the completion of the last prior therapy Recent history of a major nonCLL malignancy Evidence of an ongoing infection CLL refractory to bendamustine Concurrent participation in another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Zydelig</keyword>
	<keyword>CLL</keyword>
	<keyword>CAL 101</keyword>
	<keyword>CAL-101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>GS-1101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Leukemia</keyword>
	<keyword>idelalisib</keyword>
</DOC>